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Summary.-The prevalence ofelevated serum levels of5 potential tumour-associated
antigens was determined in patients with lung cancer sampled at the time of initial
presentation, using age- and sex-matched patients with benign lung disease as
controls. Elevated levels (> upper 95th centile of controls) were found as follows:
carcinoembryonic antigen (CEA), 17%; pregnancy-associated a-macroglobulin
(PAM), 16%; casein 140o; human chorionic gonadotrophin (HCG) 6%; a-foetoprotein
(AFP), 15%. The prevalence of elevated CEA levels (but not other markers) was
higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due
to anaplastic tumours and adenocarcinomas.
A degree of concordance of elevated marker levels occurred with CEA, HCG,
casein and AFP, but there was a striking discordance of elevated CEA and PAM
levels. Simultaneous assays of CEA and PAM will detect the majority of patients with
elevations of any of the markers studied, and are likely to be the most useful bio-
chemical markers in following the response of lung tumours to therapy.
THE recognition that neoplasia may be
associated with elevated serum levels of
protein antigens (tumour-associated anti-
gens, TAA) has prompted several studies
to define the role of such measuremnents
in the diagnosis, prognosis and manage-
ment of malignant disease (Neville and
Cooper, 1976). There is no agreement,
however, on which ofthese tests, individu-
ally or in combination, is useful in lung
cancer. In part this is due to the selection
of inappropriate control patients. Thus,
elevated CEA levels are found in '70°,/,, of
patients with lung cancer confined to the
thorax, when compared to levels in
healthy subjects (Laurence et al., 1972;
Vincent et at., 1975; Newman, Ford and
Barnes, 1976), whereas the prevalence is
considerably lower when patients with
benign lung disease are used as the
reference group (Concannon et al., 1974;
Pauwels and Van der Straeten, 1975).
We have assessed the prevalence of
elevated levels of CEA, together with 4
other TAA known to be elevated in
various malignant disorders: PAM (Stim-
son, 1975), Casein (Hendrick and Franchi-
mont, 1974), HCG (Braunstein et al.,
1973) and AFP (Laurence and Neville,
1972). By these means we hoped to assess
whether the simultaneous assay of several
markers added to the diagnostic discrimi-
nation given by CEA assays alone. The
patients were studied at the time ofinitial
presentation, using matched patients with
benign lung disease as the reference group.
METHODS
Patients studied.-Serum samples were
obtained from 197 chest-clinic patients with
lung cancer at the initial diagnosis. Diagnosis
and staging of disease with respect to extra-
thoracic spread was based upon conventional
clinical, radiological and/or bronchoscopicSERUM BIOCHEMICAL MARKERS IN LUNG CANCER
criteria. Histology was reviewed in an un-
selected group of 55 patients and classified
according to the World Health Organisation
classification by a pathologist unaware of the
clinical or laboratory data. There were 158
males (mean age 63-4 years, range 26-85)
and 39 females (mean age 61-3 years, range
45-83). Control blood samples were obtained
from 70 patients attending the same clinics
as the lung-cancer patients for a variety of
non-malignant lung disease (mainly chronic
bronchitis and tuberculosis). Diagnosis in
these patients was established by clinical,
radiological and laboratory criteria. There
were 52 males (mean age 60-7 years, range
42-86) and 18 females (mean age 59-4 years,
range 46-71). The control range for casein was
determined in a separate group of41 patients
with benign lung disease (Franchimont et al.,
1976).
Assay methods.-TAA were measured by
radioimmunoassays in unextracted sera as
follows: CEA (Laurence et al., 1972), HCG
(Vaitukaitis, Braunstein and Ross, 1972),
Casein (Hendrick and Franchimont, 1974)
and AFP (Vince et al., 1975). PAM was
determined by enzyme immunoassay (Stim-
son and Sinclair, 1974). The HCG assay
employed an antiserum raised to the : sub-
unit, and measures both intact HCG and:
HCG subunit.
RESULTS
The prevalences of elevated TAA levels
are shown in Table I. The reference ranges
for CEA, PAM and AFP are expressed in
terms of the upper 95th centile of the
controls. Separate ranges for males and
females are quoted for PAM, whereas there
is no clear sex variation for the other
antigens. HCG levels were uniformly un-
detectable (<2 pg/l) in the control group.
CEA and PAM gave the highest pre-
valences of elevated values. The propor-
tion of elevated CEA values, and to a
lesser extent casein levels, increased with
extra-thoracic spread. Elevated CEAlevels
were associated with extra-thoracic spread
in 22/97 patients (23%) and were mainly
due to small- (oat-) and large-cell anaplas-
tic tumours and adenocarcinomas (Fig.).
Although 7 samples had elevated HCG
levels, 4 were at the limit of detection of
the assay (2-4-3.0 ,ug/l).
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FIG. CEA levels in lung-cancer patients with
reviewed histology.
Some concordance of elevated HCG,
AFP and casein levels was found with
elevated CEA levels. Thus of 7 patients
with elevated HCG levels, 1 also had
elevated CEA (43 Htg/l); of the 6 with
elevated casein, 2 had elevated CEA (41
and 238 ,tg/l); and of the 2 with elevated
AFP, 1 had elevated CEA (135 Htg/l). In
contrast, there was a significant negative
correlation of CEA and PAM levels
(r-0-2193, P<0 05, n=89). All patients
with elevated CEA levels had normal PAM
levels and vice versa (Table II). The
TABLE I.-Prevalence of Elevated Levels ofTumour Markers in Lung Cancer
Tumour Upper 95th
marker centile
CEA 40 ,ug/l
PAM Males 70 mg/l
Females 130 mg/l
Casein 25 ,ug/l
HCG 2 ,ug/l
AFP 10 ,ug/l
Prevalence of elevated levels*
Localised Extrathoracic
disease spread
12/100 (12%) 22/97 (23%)
6/36 (17%) 5/39 (13%)
3/11 (27%) 1/6 (17%)
3/24 (13%) 3/18 (17%)
3/56 (5%) 4/56 (7%)
0/62 (0%) 2/72 (3%)
* Levels greater than the figure stated for the upper 95th centile for each antigen
(column 2).
Overall
prevalence
34/197 (17%)
15/92 (16%)
6/42 (14%)
7/112 (6%)
2/134 (1-5%)
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TABLE II.-Discordance between Elevated
CEA and PAM levels in Patients with
Lung Cancer
Elevated CEA levels
CEA PAM
(Kg/l) (mg/i)
240 < 0-2
43 < 0-2
395 26 -0
238 25 -0
195 < 0-2
193 9-0
140 57 0
520 12-0
55 < 0-2
220 < 0.2
135 < 0-2
340 < 0-2
45 50-0
42 22-0
195 20-0
42 18-0
Elevated PAM levels
A-
CEA
(GLg/l)
19-4
29 -3
18-0
10-8
24 0
30 0
16-7
15-2
24-0
14-8
38 0
27 -8
10-8
15 -0
20 0
PAM
(mg/,)
86
155
128
133
96
108
135
250
105
127
166
131
72
118
80
overall prevalence of elevation of one or
more markers cannot be stated with
certainty from the present study, because
it was not possible to perform all the
assays on each sample. The number of
samples assayed for each antigen is
indicated in Table I.
DISCUSSION
This study confirms that the prevalence
of diagnostically elevated CEA levels in
patients with lung cancer is relatively low
(17%) at the time of initial presentation
(i.e. CEA has low test sensitivity). The use
of patients with conditions with similar
clinical and radiographic features as the
reference group is clinically more relevant
than comparison with healthy subjects.
Thus, in the present series, 64% ofpatients
with benign lung disease had levels above
the upper limitfor healthy adults (20 ,tg/l).
The CEA level was also a poor indicator of
extra-thoracic tumour spread, being signi-
ficantly elevated in only 23%. These
figures are rather lower than others
have reported (Franchimont et al., 1976)
due, perhaps, to the nature of the refer-
ence population studied, though differ-
ences in assay specificity may also contri-
bute. CEA levels also cannot be used to
predicthistological type, althoughelevated
levels were associated more commonly
with small- (oat-) and large-cell ana-
plastic tumours and adenocarcinomas than
with squamous-cell tumours.
The prevalence and relationship of
elevated PAM levels to CEA and other
markers has not previously been reported.
As PAM levels are oestrogen-related, sex-
related reference ranges are required.
Elevated PAM levels occur in about the
same proportion of patients as CEA, but
the striking feature is the discordance
between elevated CEA and PAM levels.
This means that most of the patients with
elevated markers can be detected by
simultaneous assay ofPAM and CEA. The
significant negative correlation between
CEA and PAM levels suggests there may
be an important link between these
markers. Preliminary experiments suggest
that PAM does not act as a carrier for
CEA, so masking the CEA antigenic
site(s). This hypothesis was tested by the
separation of serum components, to which
iodinated CEA had been added, using
two-dimensional immunoelectrophoresis
and autoradiography.
Casein showed the next highest pre-
valence, and was concordant with CEA in
2 out of 6 cases. Further definition of the
role of casein assays in lung cancer would
be worthwhile. HCG assays would appear
to be less valuable, as the prevalence of
elevated levels is lower, shows some con-
cordance with CEA and many of the
values were at the limit of sensitivity.
However, the HCG assay gave no false-
positive results in non-malignant lung
disease, so that improved assay sensitivity
may increase the test sensitivity. Our
study confirms the report of Grigor et al.
(1975) that AFP assays are of no clinical
value in lung cancer.
The present data are relevant to the
selection oftests for following the response
to therapy. CEA and PAM appear to be
the most appropriate, whereas AFP and
current assays for HCG have little to
offer.
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